Date | Time | Source | Announcement |
---|---|---|---|
07 Sep 2010 | 05:08 PM | Holding(s) in Company | |
06 Sep 2010 | 07:00 AM | Distribution Agreement | |
06 Aug 2010 | 09:55 AM | Director/PDMR Shareholding | |
29 Jul 2010 | 07:00 AM | Issue of Equity | |
06 Jul 2010 | 07:00 AM | Issue of Equity | |
01 Jun 2010 | 07:00 AM | Change of Adviser | |
30 Apr 2010 | 07:00 AM | Half-yearly Report | |
08 Mar 2010 | 07:00 AM | Notice of Results and Trading | |
03 Mar 2010 | 07:00 AM | Acquisition | |
22 Feb 2010 | 02:42 PM | Director/PDMR Shareholding | |
25 Jan 2010 | 07:00 AM | Result of AGM | |
21 Dec 2009 | 10:35 AM | Issue of Equity | |
26 Nov 2009 | 07:03 AM | Preliminary Results | |
26 Nov 2009 | 07:00 AM | Issue of Equity | |
04 Nov 2009 | 07:00 AM | Notice of Results | |
21 Oct 2009 | 07:00 AM | Placing and Issue of Equity | |
06 Oct 2009 | 07:00 AM | Optim - Second Order | |
28 Sep 2009 | 07:00 AM | Re Agreement | |
16 Sep 2009 | 03:03 PM | Holding(s) in Company | |
11 Sep 2009 | 04:26 PM | Holding(s) in Company | |
11 Sep 2009 | 03:59 PM | Holding(s) in Company | |
07 Aug 2009 | 07:00 AM | Pre-Close Trading Statement | |
28 Jul 2009 | 05:07 PM | Holding(s) in Company | |
13 Jul 2009 | 04:40 PM | Director/PDMR Shareholding | |
10 Jul 2009 | 04:17 PM | Issue of Equity | |
09 Jul 2009 | 04:29 PM | Further re Acquisition of The | |
23 Apr 2009 | 07:00 AM | Half Yearly Report | |
23 Apr 2009 | 07:00 AM | OPTIM Product Launch | |
31 Mar 2009 | 12:20 PM | Analyst Presentation | |
30 Mar 2009 | 12:59 PM | Director/PDMR Shareholding | |
03 Mar 2009 | 01:17 PM | Completion of Acquisition of | |
12 Feb 2009 | 01:23 PM | Rule 8.1- (Curidium Medica Pl | |
09 Feb 2009 | 12:39 PM | Result of EGM | |
09 Feb 2009 | 07:00 AM | Acquisition | |
26 Jan 2009 | 07:00 AM | Result of AGM | |
15 Jan 2009 | 09:24 AM | Acquisition of Theragenetics Limited | |
09 Jan 2009 | 07:00 AM | Acquisition(s) | |
08 Jan 2009 | 02:29 PM | Director/PDMR Shareholding | |
07 Jan 2009 | 07:00 AM | Issue of Equity | |
12 Dec 2008 | 12:06 PM | Final Results | |
20 Nov 2008 | 04:14 PM | Director/PDMR Shareholding | |
05 Nov 2008 | 12:42 PM | Issue of Equity | |
04 Nov 2008 | 07:00 AM | Final Results | |
13 Oct 2008 | 07:00 AM | Change of Adviser | |
11 Sep 2008 | 07:00 AM | Product Launch | |
21 Aug 2008 | 07:00 AM | Trading Statement | |
14 Aug 2008 | 11:03 AM | Product Development Partnership | |
28 Jul 2008 | 07:00 AM | Product Launch | |
23 Jul 2008 | 02:54 PM | Director/PDMR Shareholding | |
22 Jul 2008 | 04:24 PM | Director/PDMR Shareholding |
Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.
It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.
Avacta Group share price launched at 5,448p in 2003.